Wealth Advisory Solutions LLC Boosts Position in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)

Wealth Advisory Solutions LLC boosted its stake in shares of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) by 33.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 201,000 shares of the company’s stock after buying an additional 50,000 shares during the quarter. Wealth Advisory Solutions LLC’s holdings in Citius Pharmaceuticals were worth $101,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in CTXR. Point72 DIFC Ltd bought a new stake in shares of Citius Pharmaceuticals during the second quarter valued at approximately $29,000. BNP Paribas Financial Markets raised its position in Citius Pharmaceuticals by 88.5% during the 1st quarter. BNP Paribas Financial Markets now owns 69,615 shares of the company’s stock valued at $62,000 after purchasing an additional 32,686 shares in the last quarter. Cubist Systematic Strategies LLC bought a new stake in Citius Pharmaceuticals during the 2nd quarter valued at $69,000. Arkadios Wealth Advisors lifted its holdings in shares of Citius Pharmaceuticals by 50.0% in the 2nd quarter. Arkadios Wealth Advisors now owns 150,000 shares of the company’s stock worth $88,000 after buying an additional 50,000 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Citius Pharmaceuticals during the 2nd quarter worth $118,000. 16.88% of the stock is owned by hedge funds and other institutional investors.

Citius Pharmaceuticals Trading Down 1.3 %

Shares of CTXR traded down $0.01 during mid-day trading on Monday, hitting $0.39. The company’s stock had a trading volume of 112,689 shares, compared to its average volume of 1,449,540. The company’s 50-day moving average is $0.52 and its 200-day moving average is $0.66. Citius Pharmaceuticals, Inc. has a 52-week low of $0.34 and a 52-week high of $1.07. The firm has a market capitalization of $69.70 million, a price-to-earnings ratio of -1.63 and a beta of 1.61.

Citius Pharmaceuticals (NASDAQ:CTXR) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). As a group, sell-side analysts predict that Citius Pharmaceuticals, Inc. will post -0.21 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, EF Hutton Acquisition Co. I upgraded Citius Pharmaceuticals to a “strong-buy” rating in a report on Monday, July 15th.

Citius Pharmaceuticals Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.